InMode (NASDAQ: INMD) is one of 51 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare InMode to related businesses based on the strength of its risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.


This table compares InMode and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InMode 39.10% 52.38% 41.08%
InMode Competitors -233.15% -74.62% -10.50%

Valuation & Earnings

This table compares InMode and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
InMode $156.36 million $61.15 million 14.20
InMode Competitors $1.12 billion $126.03 million 16.94

InMode’s rivals have higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations for InMode and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode 0 0 4 0 3.00
InMode Competitors 332 872 1542 80 2.48

InMode presently has a consensus price target of $45.25, indicating a potential upside of 99.16%. As a group, “Electromedical equipment” companies have a potential upside of 56.10%. Given InMode’s stronger consensus rating and higher possible upside, equities research analysts plainly believe InMode is more favorable than its rivals.

Insider and Institutional Ownership

11.2% of InMode shares are held by institutional investors. Comparatively, 47.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


InMode beats its rivals on 6 of the 11 factors compared.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with's FREE daily email newsletter.